Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ.
Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ.
Labcorp宣佈美國食品藥品管理局批准其NabCyte抗AAVRH74VAR HB-FE試驗（一種伴隨診斷），以確定患者是否有資格接受BEQVEZ治療，此後，Labcorp股價走高。
Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ.
Labcorp宣佈美國食品藥品管理局批准其NabCyte抗AAVRH74VAR HB-FE試驗（一種伴隨診斷），以確定患者是否有資格接受BEQVEZ治療，此後，Labcorp股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。